Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadekinig alfa OLE in NLRC4/XIAP autoinflammatory conditions
NCT03512314Phase 3Completed
- Sponsor
- AB2 Bio Ltd.
- Start
- Jan 2018
- Primary completion
- Apr 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of tadekinig alfa in NLRC4-associated macrophage activation syndrome (NLRC4-MAS), X-linked inhibitor of apoptosis protein deficiency, sponsored by AB2 Bio Ltd.. Started Jan 2018; status: completed.
02
Drugs
tadekinig alfa
03
Conditions
NLRC4-associated macrophage activation syndrome (NLRC4-MAS)X-linked inhibitor of apoptosis protein deficiency
Beyond the preview
Go deeper on NCT03512314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512314.